| Related Articles |
Potential Relief for Refractory Angina.
N Engl J Med. 2015 Feb 5;372(6):566-567
Authors: Granger CB, Gersh BJ
Abstract
Physicians who practice primarily in outpatient settings are faced with a large and growing population of patients with chronic, stable, but refractory angina,(1),(2) as a consequence of an aging population and our ability to prolong the lives of patients with coronary disease. The mortality among patients with refractory angina is surprisingly low,(3) but the effect of persistent, recurrent, and frequent symptoms on quality of life is substantial and emphasizes the need for alternative therapeutic options. The newest drug in this therapeutic area, ivabradine, which is approved in Europe, has been shown to reduce angina and improve exercise time in . . .
PMID: 25651252 [PubMed - as supplied by publisher]